Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Johnson & Johnson

- PMLiVE

Janssen announces new group to tackle global health

Will implement R&D and access strategies to support areas with unmet public health need

J&J expected to make best use of digital in 2014

Company's strong approach to marketing strategy praised in Digital Futures 2014 survey

- PMLiVE

J&J earnings leap on buoyant pharma sales

CEO Alex Gorsky praises "outstanding" pharmaceutical performance

- PMLiVE

Xarelto should not be approved in ACS says FDA panel

Advisory committee votes against new indication for Bayer and J&J’s anticoagulant

- PMLiVE

J&J’s Imbruvica tops Arzerra in phase III trial

Shows improvement over GSK’s drug in haematological malignancies

- PMLiVE

FDA panel backs Takeda’s inflammatory bowel disease drug

Vedolizumab on course for US approval to treat Crohn’s disease and ulcerative colitis

Patient Power: Too Much of a Good Thing?

Mary Assimakopoulos, reveals findings from the company’s Therapy Watch market research data, investigating patient behaviour in Crohn’s Disease and discusses how pharma can benefit from improved patient understanding

Research Partnership

- PMLiVE

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

- PMLiVE

GSK hands back rights to ChemoCentryx drug

Investigational IBD treatment vercirnon disappoints in phase III

- PMLiVE

J&J hit by more recalls

Withdraws 200,000 bottles of cough drops in US

- PMLiVE

FDA grants priority review to Takeda’s colitis drug

Accelerates review time for vedolizumab

- PMLiVE

J&J files rare blood disorder drug siltuximab in US and EU

Orphan drug to be assessed for use in the treatment of multicentric Castleman disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links